Author

F. Rothweiler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Assay:bulk RNA-seq· 5 Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

J. Cinatl· 6 shared M. Michaelis· 5 shared M. N. Wass· 5 shared T. Rothenburger· 3 shared C. Schneider· 2 shared D. Bojkova· 2 shared F. Roedel· 2 shared K.-M. McLaughlin· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersPharmacology & Toxicology

J. Cinatl

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

D. Bojkova, P. Reus, L. Panosch, M. Bechtel, T. Rothenburger, J. Kandler, A. Pfeiffer, J. U. Wagner, M. Shumliakivska, S. Dimmeler, R. Olmer, U. Martin, F. Vondran, T. Toptan, F. Rothweiler, , J. Cinatl

This study develops a phenotypic screening platform using caspase 3/7 activity to identify antiviral compounds against SARS-CoV-2, including novel candidates and combinations.

bioRxiv · Jul 17, 2022Pharmacology & Toxicology

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells

T. Rothenburger, D. Thomas, Y. Schreiber, P. R. Wratil, T. Pflantz, K. Knecht, K. Digianantonio, J. Temple, C. Schneider, H.-M. Baldauf, K.-M. McLaughlin, F. Rothweiler, B. Bilen, S. Farmand, D. Bojkova, , J. Cinatl

This study identifies intrinsic and acquired resistance mechanisms to CNDAC and related nucleoside analogues in AML cells, showing distinct roles of SAMHD1 and DCK.

bioRxiv · Jul 19, 2021Pharmacology & Toxicology

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

M. Michaelis, M. N. Wass, I. Reddin, Y. Voges, F. Rothweiler, S. Hehlgans, J. Cinatl, M. Mernberger, A. Nist, T. Stiewe, F. Roedel, J. Cinatl

The paper investigates drug-induced heterogeneity in cancer cell lines and identifies biomarkers for acquired resistance to YM155.

bioRxiv · Feb 13, 2020Pharmacology & Toxicology

Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines

M. Michaelis, Y. Voges, F. Rothweiler, F. Weipert, A. Zhia-Amad, J. Cinatl, A. von Deimling, F. Westermann, F. Roedel, M. N. Wass, J. Cinatl

This study tests YM155 in 101 neuroblastoma cell lines, revealing ABCB1 and ABCC1 as mediators of resistance and highlighting cross-resistance differences between drug-adapted lines.

bioRxiv · Jan 27, 2020Pharmacology & Toxicology

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine

T. Rothenburger, K.-M. McLaughlin, T. Herold, C. Schneider, T. Oellerich, F. Rothweiler, A. Feber, T. R. Fenton, M. N. Wass, O. Keppler, M. N. Michaelis, J. Cinatl

This study identifies SAMHD1 as a key regulator of nelarabine response in acute lymphoblastic leukaemias, showing lineage-specific differences in SAMHD1 expression and methylation.

bioRxiv · Dec 3, 2019Pharmacology & Toxicology

The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation

J.-U. Vogel, S. Schmidt, D. Schmidt, F. Rothweiler, B. Koch, P. C. Baer, H. F. Rabenau, D. Michel, T. Stamminger, M. Michaelis, J. Cinatl

This paper shows eltrombopag inhibits HCMV replication via iron chelation, effective against drug-resistant strains and synergistic with ganciclovir.

bioRxiv · Nov 1, 2019Pharmacology & Toxicology